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Results: Thirty-four patients were enrolled and treated. Patient 
characteristics were: ECOG performance status 0 in 24 patients, 1 in 
10 patients, median age 63 years (range 39-78), and gender male 20, 
female 14. Dose-escalation was possible to erlotinib 150mg/day for 
both regimens during chemoradiotherapy. Grade 3/4 leukopenia and 
neutropenia were noted in both arms. No Grade 4 therapy-related non-
hematologic toxicities were noted. For arm A, grade 3 toxicities during 
chemoradiotherapy were: esophagitis (3), vomiting (1), ototoxicity (1), 
diarrhea (2), dehydration (3), pneumonitis (1). For arm B, esophagitis 
(6) was the dominant grade 3 toxicity. Rash developed in 7 patients 
(21%). Twenty-seven patients (79%) completed their assigned regimen 
and were evaluable for response (Arm A - 12, Arm B - 15). Reasons 
for discontinuation were: adverse event (3), withdrawal of consent (2), 
non-compliance (1) and non-cancer related early death (1). Overall 
radiologic responses were (Arm A/B): Complete Response (0/1), 
Partial Response (8/9), Stable Disease (1/2) and Progressive Disease 
(3/3). Intention-to-treat 1- and 2- overall survivals were 47% and 21%, 
respectively. Overall and median survivals between the two arms were 
not signiﬁcantly different. In the patients who developed a rash (7), 1 
complete and 4 partial responses were observed. This group of patients 
had a trend towards improved overall survival (log-rank 0.07).
Conclusion: The addition of erlotinib to two standard chemoradio-
therapy regimens is feasible and does not increase toxicities associated 
with chemoradiotherapy.
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Background: Neither the optimal sequence of treatment nor the best 
combination CT is yet well-deﬁned in p receiving concomitant therapy. 
Methods: P with unresectable stage III NSCLC with IK > 70 and 
weight loss < 5% were initially randomized to sequential treatment 
(arm A), concurrent CT/TRT followed by consolidation (C) CT (arm 
B) or induction (I) CT followed by CT/TRT (arm C). Based on RTOG 
9410 results, arm A was closed and the study continues with two 
concomitant arms (B, C). All p receive 2 cycles of Docetaxel (D) 40 
mg/m2 d1, 8 plus Gemcitabine (G) 1200 mg/m2 d1, 8 as I or C therapy. 
Concomitant treatment includes D 20 mg/m2 and carboplatin (Cb) AUC 
2 weekly plus 60 Gy TRT. 
Results: From May 01 to Jun 06, 151 p were included (A: 19, B: 66, C: 
66). Due to the early closing of arm A, only data of evaluable arms B 
and C p are shown: toxicity 127 p (B: 63, C: 64) and response 110 p (B: 
53, C: 57). All groups are well-matched for baseline disease character-
istics. Toxicity grade 3-4 by CTC and RTOG criteria was: esophagitis 
19.5% (arm B) and 14.2% (arm C); pneumonitis 8.8 % (arm B) and 
10% (arm C). Neutropenia during I or C therapy: 22 % (B) and 6.2 
% (C). Thrombocytopenia 8% (B) and 3% (C). Neutropenia during 
concomitant therapy: 6.3% (B) and 6% (C). No thrombocytopenia or 
severe anemia was found during CT/TRT. The reduction CT rate was 
superior in consolidation (35%) than in induction (15%) and in arm C 
during concomitant therapy (22.4% C, 6.5% B). Delay of CT dose was 
similar in B and C arms during I or C (22% B, 20% C) but superior 
in arm C during concurrent treatment (19.6% B, 30.6% C). The ﬁnal 
response rates were 57% (B) and 56.9% (C). A trend for longer time to 
progression (TTP) was found (B: 7.6 months (m) and C: 9.2 m; p= 0.12) 
but with similar overall survival (B: 14.3 m and C: 14.7 m; p= 0.38). 
Conclusions: Non-platinum CT plus concomitant chemoradiation offer 
similar response rate and a favorable hematological toxicity proﬁle in 
unresectable stage III NSCLC p. No differences in OS but a trend for 
longer TTP in the arm C (I followed by concurrent approach) has been 
found. Final data are pending in order to select the best sequence for 
further studies.
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Background: Combined modality therapy using both chemotherapy 
and TRT is the standard treatment option in unrectable stage III 
NSCLC. Our group demonstrated a superiority of MVP with concur-
rent TRT over that with sequential TRT (Furuse et al. JCO 17, 1999). 
Currently, concurrent chemoradiotherapy plays a pivotal role in this pa-
tient population. However, the optimal chemotherapy regimen remains 
unclear. Weekly chemotherapy with concurrent TRT has acceptable 
toxicities and expected efﬁcacy. We conducted a randomized phase III 
trial to compare the efﬁcacy and toxicity of weekly chemotherapy with 
concurrent TRT against MVP by a non-inferiority design. 
Methods: Patients (pts) were randomly assigned to 3 regimens; MVP: 
cisplatin (80 mg/m2 on days 1, 29), vindesine (3 mg/m2 on days 1, 8, 
29, 36) and mitomycin (8 mg/m2 on days 1, 29) with concurrent TRT 
(60 Gy). After then, pts received 2 courses of consolidation chemo-
therapy with MVP; IC: weekly irinotecan (20 mg/m2)/carboplatin(AUC 
2) for 6 weeks and TRT (60 Gy) followed by 2 courses of irinotecan(50 
mg/m2)/carboplatin(AUC 5); PC: weekly paclitaxel (40 mg/m2)/carbo-
platin (AUC 2) and TRT (60 Gy) followed by 2 courses of paclitaxel 
(200 mg/m2)/carboplatin (AUC 5). The primary endpoint was overall 
survival; secondary endpoints were time to progression, response, and 
toxicity. 
Results: From Sep 2001 to Sep 2005, 456 pts were randomized; 429 
pts had evaluated responses. Pretreatment characteristics were well-bal-
anced between 3 arms (median age 63 years (30-74), PS0/1 41/55 %, 
Ad/Sq /others 43/ 45/12 %). The achievement rates of full treatment in 
MVP, IC and PC were 39.9, 29.7, and 49.3 %; those of full-dose TRT / 
